My Treatment Approach: Metastatic Melanoma : Episode 3
First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: Ipilimumab & Nivolumab
Dr Michael Atkins and Dr Evan Lipson review data from the DREAMseq trial, which evaluated nivolumab plus ipilimumab, in treatment-naïve patients with BRAFV600-mutated melanoma.
EP: 1.The Current State of Metastatic Melanoma
EP: 2.First-line and Subsequent Treatment Strategies for Unresectable/Metastatic Melanoma: A Patient Profile
Now Viewing
EP: 3.First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: Ipilimumab & Nivolumab
EP: 4.First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: BRAF/MEK Inhibitors
EP: 5.First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: Unmet Needs
EP: 6.Frontline Trials for BRAF-Mutant Metastatic Melanoma: Relatlimab Plus Nivolumab
EP: 7.Second-line Treatment Strategies for BRAF-mutant Metastatic Melanoma: Patient Profile Revisited
EP: 8.Second-line Treatment Strategies for BRAF-mutant Metastatic Melanoma: Additional Patient Scenarios
EP: 9.Closing Remarks on the Treatment of Patients With Metastatic Melanoma
Related Videos
Related Content
